Clinical Trials Logo

Myasthenia Gravis, Generalized clinical trials

View clinical trials related to Myasthenia Gravis, Generalized.

Filter by:

NCT ID: NCT04115293 Completed - Clinical trials for Myasthenia Gravis, Generalized

Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis

RAISE
Start date: September 17, 2019
Phase: Phase 3
Study type: Interventional

The RAISE study is a multicenter, randomized, double-blind, placebo controlled study to confirm the efficacy, safety, and tolerability of zilucoplan in subjects with generalized Myasthenia Gravis. Subjects will be randomized in a 1:1 ratio to receive daily SC doses of 0.3 mg/kg zilucoplan or placebo for 12 weeks.

NCT ID: NCT03759366 Completed - Myasthenia Gravis Clinical Trials

A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refractory Generalized Myasthenia Gravis (gMG)

Start date: December 21, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of eculizumab in the treatment of pediatric refractory gMG based on change from Baseline in the Quantitative Myasthenia Gravis (QMG) score for disease severity.

NCT ID: NCT03304054 Completed - Clinical trials for Myasthenia Gravis, Generalized

Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG

Start date: April 18, 2018
Phase: Phase 3
Study type: Interventional

Efficacy and safety of amifampridine phosphate in improving the activities of daily living for patients with antibody positive MuSK myasthenia gravis.

NCT ID: NCT03165435 Withdrawn - Clinical trials for Myasthenia Gravis, Generalized

A Study to Evaluate the Efficacy of CV-MG01 (Myasterix) in Myasthenia Gravis

Start date: July 2018
Phase: Phase 2/Phase 3
Study type: Interventional

Study CV-0003 will be the second clinical trial administering CV-MG01 in humans. This will be a phase 2/3 proof-of-efficacy therapeutic confirmatory study following the proof-of-concept exploratory phase 1 study (CV-0002).

NCT ID: NCT02565576 Completed - Clinical trials for Myasthenia Gravis, Generalized

Safety,Tolerability,Pharmacokinetics and Efficacy of CFZ533 in Moderate to Severe Myasthenia Gravis

Start date: September 29, 2015
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate safety, tolerability, pharmacokinetics/pharmacodynamics and efficacy of CFZ533 as an add-on therapy to standard of care in patients with moderate to severe myasthenia gravis (MG).

NCT ID: NCT02473952 Completed - Clinical trials for Myasthenia Gravis, Generalized

A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis

Start date: August 2015
Phase: Phase 2
Study type: Interventional

The primary objective is to evaluate whether IGIV-C improves MG symptoms as compared to placebo in subjects with MG.

NCT ID: NCT00683969 Completed - Clinical trials for Myasthenia Gravis, Generalized

A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Controlling Symptoms of Myasthenia Gravis

Start date: August 2004
Phase: Phase 3
Study type: Interventional

The efficacy and safety of CellCept (1g po, bid for 36 weeks) will be assessed in patients with myasthenia gravis receiving prednisone, or other corticosteroids. During the study, patients will undergo gradual corticosteroid dose reduction, if they respond to treatment. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.